The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 355:2788-2791 December 28, 2006 Number 26
NextNext

Enoxaparin in Elective Percutaneous Coronary Intervention

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Montalescot, G.
-PubMed Citation
To the Editor: In their report on the Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention Patients, an International Randomized Evaluation (STEEPLE) trial (Sept. 7 issue),1 Montalescot et al. highlight the important issue of bleeding in coronary intervention. I noted the distinctive nature of the definitions the investigators used and the exclusion of patients with a high risk of bleeding. In the STEEPLE trial, there was wide variation in the frequency of bleeding according to the classification criteria used — the STEEPLE criteria, the Thrombolysis in Myocardial Infarction (TIMI) criteria,2 or the Global Utilization of Streptokinase and Tissue Plasminogen . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.